Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter July 5, 2005

Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients

Ricardo Hermo , Cristina Mier , Mary Mazzotta , Masatomi Tsuji , Satoshi Kimura and Alejandro Gugliucci


Recent work has shown that high-density lipoprotein (HDL) isolated from human atherosclerotic lesions and the blood of patients with established coronary artery disease contains elevated levels of 3-nitrotyrosine and 3-chlorotyrosine. A higher nitrotyrosine content in lipoprotein is significantly associated with diminished cholesterol efflux capacity of the lipoprotein. Since accelerated atherogenesis is a key complication of diabetes mellitus, and nitrosative stress has recently been implicated in diabetic pathology, we set out to demonstrate an increase in the circulating levels of nitrated apolipoprotein A (apoA)-I in type 2 diabetic patients and its putative correlation with metabolic biomarkers. In this work we addressed this hypothesis in a case-control study with 30 type 2 diabetic patients and 30 age-matched control subjects. Nitrated apoA-I was 3280±1910 absorbance peak area/apoA-I (g/L) for diabetic patients and 2320±890 for control subjects (p<0.037). This represents a 50% increase in circulating nitrated apoA-I in diabetic patients to age-matched controls. Diabetic patients also showed increases of a similar magnitude in circulating advanced glycation endproducts measured as pentosidine fluorescence (44.16±16.26 vs. 30.84±12.86 AU; p<0.01) and in circulating lipoperoxides (46.0±18.0 vs. 37.2±18.0nmol/L; p<0.03). No significant correlation was found between nitration of apoA-I and glycosylated hemoglobin or any of the other parameters measured. If proven in subsequent functional and in vivo studies, increased nitrated apoA-I would represent another mechanism by which nitrosative stress participates in diabetic macro-angiopathy.

Corresponding author: Alejandro Gugliucci, MD, PhD, Research Director, Professor of Biochemistry, Touro University-California, Mare Island Building H-83, 1310, Johnson Lane, Vallejo, CA 94592, USA Phone: +1-707-6385237, Fax: +1-707-6385255,


1 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44–54. 10.1016/S1056-8727(00)00132-XSearch in Google Scholar

2 Jakus V. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease. Bratisl Lek Listy 2000; 101: 541–51. Search in Google Scholar

3 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570–81. 10.1001/jama.287.19.2570Search in Google Scholar

4 Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 241–52. Search in Google Scholar

5 Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258–68. 10.2337/diacare.18.2.258Search in Google Scholar

6 Turner RC Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract 1995; 28( Suppl): S151–7. 10.1016/0168-8227(95)01105-MSearch in Google Scholar

7 Calles-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999; 10: 23–30. 10.1097/00019501-199901000-00004Search in Google Scholar

8 Lobo RA. Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease. Am J Obstet Gynecol 1988; 158: 1584–91. 10.1016/0002-9378(88)90194-9Search in Google Scholar

9 Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997; 20: 426–32. 10.1002/clc.4960200505Search in Google Scholar

10 Miller GJ. Postprandial lipaemia and haemostatic factors. Atherosclerosis 1998; 141(Suppl) 1: S47–51. 10.1016/S0021-9150(98)00217-2Search in Google Scholar

11 Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073–84. 10.1096/fj.01-0273revSearch in Google Scholar PubMed

12 Gugliucci Creriche A, Stahl AJ. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand J Clin Lab Invest 1993; 53: 125–32. 10.3109/00365519309088399Search in Google Scholar PubMed

13 Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28: 1708–16. 10.1016/S0891-5849(00)00228-8Search in Google Scholar

14 Gugliucci A, Stahl AJ. In vitro glycation of human apolipoprotein AI reduces its efficiency in lecithin: cholesterol acyltransferase activation. Clin Chim Acta 1991; 204: 37–42. 10.1016/0009-8981(91)90214-WSearch in Google Scholar

15 Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, et al. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002; 51: 2817–25. 10.2337/diabetes.51.9.2817Search in Google Scholar PubMed

16 Cakatay U, Telci A, Salman S, Satman L, Sivas A. Oxidative protein damage in type I diabetic patients with and without complications. Endocr Res 2000; 26: 365–79. 10.3109/07435800009066174Search in Google Scholar PubMed

17 Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44: 834–8. 10.1007/s001250100529Search in Google Scholar PubMed

18 Ceriello A. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int J Clin Pract Suppl 2002; 129: 51–8. Search in Google Scholar

19 Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439–43. 10.2337/diacare.25.8.1439Search in Google Scholar PubMed

20 Gugliucci A. Human plasminogen is highly susceptible to peroxynitrite inactivation. Clin Chem Lab Med 2003; 41: 1064–8. 10.1515/CCLM.2003.164Search in Google Scholar PubMed

21 Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529–41. 10.1172/JCI200421109Search in Google Scholar

22 Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005; 280: 38–47. 10.1074/jbc.M407019200Search in Google Scholar PubMed

23 Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1964; 6: 24–8. 10.1177/000456326900600108Search in Google Scholar

24 Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470–5. 10.1093/clinchem/20.4.470Search in Google Scholar

25 Nagele U, Hagele E, Sauer G. Reagent for the enzymatic determinations of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Biochem 1984; 22: 165–74. 10.1515/cclm.1984.22.2.165Search in Google Scholar

26 Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 1994; 32: 9–15. 10.1385/0-89603-268-X:9Search in Google Scholar

27 Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1–21. 10.1210/rp.56.1.1Search in Google Scholar

28 Nagaraj RH, Oya-Ito T, Padayatti PS, Kumar R, Mehta S, West K, et al. Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 2003; 42: 10746–55. 10.1021/bi034541nSearch in Google Scholar

29 el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989; 30: 627–30. 10.1016/S0022-2275(20)38354-1Search in Google Scholar

30 Brewer HB, Ronan R, Meny M, Bishop C. Isolation and characterization of apolipoproteins A I and A II. Methods Enzymol 1996; 128: 233–47. Search in Google Scholar

31 Onorato JM, Thorpe SR, Baynes JW. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann NY Acad Sci 1998; 854: 277–90. 10.1111/j.1749-6632.1998.tb09909.xSearch in Google Scholar PubMed

32 Pignatelli B, Li CQ, Boffetta P, Chen Q, Ahrens W, Nyberg F, et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001; 61: 778–8. Search in Google Scholar

33 Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2004; 280: 5983–93. 10.1074/jbc.M411484200Search in Google Scholar PubMed

34 Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004; 15: 269–78. 10.1097/00041433-200406000-00006Search in Google Scholar PubMed

35 Lacinski M, Skorupski W, Cieslinski A, Sokolowska J, Trzeciak WH, Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol 2004; 50: 885–93. Search in Google Scholar

Received: 2005-1-25
Accepted: 2005-4-14
Published Online: 2005-7-5
Published in Print: 2005-6-1

© Walter de Gruyter Berlin New York

Downloaded on 10.12.2022 from
Scroll Up Arrow